GT BIOPHARMA, INC.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $10.3M | $32.2M | $9.0M |
| FY2022 | $5.0M | $16.7M | $5.7M |
| FY2023 | $6.6M | $14.1M | $1.1M |
| FY2024 | $5.9M | $4.2M | $4.0M |
| FY2025 | $31.0M | $7.1M | $6.8M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $10.3M | $32.2M | $9.0M |
| FY2022 | $5.0M | $16.7M | $5.7M |
| FY2023 | $6.6M | $14.1M | $1.1M |
| FY2024 | $5.9M | $4.2M | $4.0M |
| FY2025 | $31.0M | $7.1M | $6.8M |